- Home
- CSBR vs CGEN Comparison
CSBR vs CGEN Comparison
Compare CSBR & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- CGEN
- Stock Information
- Founded
- CSBR 1985
- CGEN 1993
- Country
- CSBR United States
- CGEN Israel
- Employees
- CSBR N/A
- CGEN N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSBR Health Care
- CGEN Health Care
- Exchange
- CSBR Nasdaq
- CGEN Nasdaq
- Market Cap
- CSBR 113.0M
- CGEN 135.6M
- IPO Year
- CSBR 1986
- CGEN 2000
- Fundamental
- Price
- CSBR $7.90
- CGEN $1.48
- Analyst Decision
- CSBR Strong Buy
- CGEN Strong Buy
- Analyst Count
- CSBR 1
- CGEN 1
- Target Price
- CSBR $12.00
- CGEN $4.00
- AVG Volume (30 Days)
- CSBR 36.4K
- CGEN 253.2K
- Earning Date
- CSBR 03-11-2025
- CGEN 05-19-2025
- Dividend Yield
- CSBR N/A
- CGEN N/A
- EPS Growth
- CSBR N/A
- CGEN N/A
- EPS
- CSBR 0.46
- CGEN N/A
- Revenue
- CSBR $58,591,000.00
- CGEN $27,864,000.00
- Revenue This Year
- CSBR $15.11
- CGEN $11.81
- Revenue Next Year
- CSBR $7.80
- CGEN $28.37
- P/E Ratio
- CSBR $17.27
- CGEN N/A
- Revenue Growth
- CSBR 19.03
- CGEN N/A
- 52 Week Low
- CSBR $3.60
- CGEN $1.13
- 52 Week High
- CSBR $11.99
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- CSBR 43.84
- CGEN 51.43
- Support Level
- CSBR $7.61
- CGEN $1.13
- Resistance Level
- CSBR $8.86
- CGEN $1.50
- Average True Range (ATR)
- CSBR 0.69
- CGEN 0.10
- MACD
- CSBR 0.04
- CGEN 0.04
- Stochastic Oscillator
- CSBR 44.28
- CGEN 97.30
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.